# EDGAR Filing Document

**Accession Number:** 0001705843
**File Stem:** 0001628280-26-035159
**Filing Date:** 2026-5
**Character Count:** 118617
**Document Hash:** b132e30dab945170b897dc96ee2a8d95
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-035159.hdr.sgml**: 20260514

**ACCESSION NUMBER**: 0001628280-26-035159

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 84

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260514

**DATE AS OF CHANGE**: 20260514

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cibus, Inc.
- **CENTRAL INDEX KEY:** 0001705843
- **STANDARD INDUSTRIAL CLASSIFICATION:** AGRICULTURE CHEMICALS [2870]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 271967997
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38161
- **FILM NUMBER:** 26979831

**BUSINESS ADDRESS:**
- **STREET 1:** 6455 NANCY RIDGE DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** (858) 450-0008

**MAIL ADDRESS:**
- **STREET 1:** 6455 NANCY RIDGE DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Calyxt, Inc.
- **DATE OF NAME CHANGE:** 20170504

?xml version='1.0' encoding='ASCII'? cbus-20260331

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

_____________________

**FORM 10-Q**

_____________________

**(Mark One)** 

⌧ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2026;** 

**or** 

□ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from_________to_________**

**Commission file number 001-38161**

![Cibus New Logo.jpg](cbus-20260331_g1.jpg)

_____________________

**Cibus, Inc.**

**(Exact name of registrant as specified in its charter)** 

_____________________

---

| | |
|:---|:---|
| **Delaware** | **27-1967997** |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(I.R.S. Employer<br>Identification No.)** |
| **6455 Nancy Ridge Drive**<br>**San Diego, CA** | **92121** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(858) 450-0008**

**(Registrant's telephone number, including area code)** 

**N/A** 

**(Former name, former address and former fiscal year, if changed since last report)** 

_____________________

**Securities registered pursuant to Section 12(b) of the Act.** 

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| Class A Common Stock, $0.0001 par value per share | CBUS | The NASDAQ Stock Market LLC |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | □ | Accelerated filer | □ |
| Non-accelerated filer | ⌧ | Smaller reporting company | ⌧ |
| | | Emerging growth company | □ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). □ Yes ⌧ No

As of May 8, 2026, there were 76,331,634 shares of the registrant's Class A Common Stock, $0.0001 par value per share (Class A Common Stock) outstanding (excluding 52,045 restricted shares of Class A Common Stock, which remain subject to vesting), and no shares of the registrant's Class B Common Stock, $0.0001 par value per share, outstanding.

------

---

| | |
|:---|:---|
| **Table of Contents** | **Table of Contents** |
| <u>[PART I. FINANCIAL INFORMATION](#ibc96409b9b73482eb520d67c87da1c7a_274)</u> | [4](#ibc96409b9b73482eb520d67c87da1c7a_274) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 1. Condensed Consolidated Financial Statements](#ibc96409b9b73482eb520d67c87da1c7a_277)</u> | [4](#ibc96409b9b73482eb520d67c87da1c7a_277) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#ibc96409b9b73482eb520d67c87da1c7a_286)</u> | [23](#ibc96409b9b73482eb520d67c87da1c7a_286) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 4. Controls and Procedures](#ibc96409b9b73482eb520d67c87da1c7a_292)</u> | [28](#ibc96409b9b73482eb520d67c87da1c7a_292) |
| <u>[PART II. OTHER INFORMATION](#ibc96409b9b73482eb520d67c87da1c7a_295)</u> | [29](#ibc96409b9b73482eb520d67c87da1c7a_295) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 1. Legal Proceedings](#ibc96409b9b73482eb520d67c87da1c7a_298)</u> | [29](#ibc96409b9b73482eb520d67c87da1c7a_298) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 1A. Risk Factors](#ibc96409b9b73482eb520d67c87da1c7a_301)</u> | [29](#ibc96409b9b73482eb520d67c87da1c7a_301) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#ibc96409b9b73482eb520d67c87da1c7a_304)</u> | [29](#ibc96409b9b73482eb520d67c87da1c7a_304) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 5. Other Information](#ibc96409b9b73482eb520d67c87da1c7a_307)</u> | [29](#ibc96409b9b73482eb520d67c87da1c7a_307) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 6. Exhibits](#ibc96409b9b73482eb520d67c87da1c7a_313)</u> | [30](#ibc96409b9b73482eb520d67c87da1c7a_313) |
| <u>[SIGNATURES](#ibc96409b9b73482eb520d67c87da1c7a_316)</u> | [31](#ibc96409b9b73482eb520d67c87da1c7a_316) |

---

**Terms** 

When the terms "Cibus," the "Company" or "its" are used in this Quarterly Report on Form 10-Q, unless the context otherwise requires, those terms are being used to refer to Cibus, Inc. and its consolidated subsidiaries. When the term "Cibus Global" is used, it is being used to refer to Cibus Global, LLC, a direct, wholly-owned subsidiary of the Company.

The Company owns or has the right to use the trademarks, service marks, and trade names that it uses in conjunction with the operation of its business. Some of the more important marks and names that it owns or has rights to use that may appear in this Quarterly Report on Form 10-Q include: "Cibus<sup>®</sup>," "***RTDS***<sup>®</sup>," "Rapid Trait Development System<sup>TM</sup>," "Trait Machine<sup>TM</sup>," and "Future of Breeding<sup>TM</sup>." This Quarterly Report on Form 10-Q may also contain additional trade names, trademarks, and service marks belonging to other companies. The Company does not intend its use or display of other parties' trademarks, trade names, or service marks to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of these other parties.

**Cautionary Note Regarding Forward-Looking Statements** 

This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the Securities Act) and the rules and regulations promulgated thereunder, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act) and the rules and regulations promulgated thereunder. The Company may also make forward-looking statements in other reports filed with the Securities and Exchange Commission (SEC), in materials delivered to stockholders, and in press releases. In addition, the Company's representatives may from time-to-time make oral forward-looking statements.

The Company has made these forward-looking statements in reliance on the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, level of activity, performance or achievements. In some cases, you can identify these statements by forward-looking words such as "anticipates," "believes," "continue," "could," "estimates," "expects," "intends," "may," "might," "plans," "predicts," "projects," "scheduled," "should," "targets," "will," "would," or the negative of these terms and other similar terminology. Forward-looking statements in this Quarterly Report on Form 10-Q include statements about the Company's future financial performance, including its liquidity and capital resources, cost saving initiatives and their impact on annual cash burn rates, cash runway, and its ability to continue as a going concern; the advancement, timing and progress of the Company's platform development and trait development in crop platforms; the ability to obtain partner funding to support its non-Rice productivity trait portfolio; the anticipated timing for the presentation of data related to trait development and other operational activities; the timeframes for transferring traits in customers' elite germplasm; the timeframe for commercialization of germplasm with the Company's traits by seed company customers; the timing for, and degree of, adoption by farmers of germplasm with the Company's traits following commercialization; the capacity of the Company's productivity traits to deliver competitive yield improvements; the ability of gene editing to address climate change at scale; the timing and nature of regulatory developments relating to gene editing; the market opportunity for the Company's plant traits, including the number of addressable acres, and the trait fees that the Company expects to receive; and the Company's ability to enter into and maintain significant collaborations and commercial relationships. These and other forward-looking statements are predictions and projections about future events and trends based on the Company's current expectations, objectives, and intentions and are premised on current assumptions. The Company's actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: the Company's need for additional near-term funding to finance its activities and challenges in obtaining additional capital on acceptable terms, or at all; changes in expected or existing competition; challenges to the Company's intellectual property protection and unexpected costs associated with defending intellectual property rights; increased or unanticipated

------

time and resources required for the Company's development efforts for its priority opportunities in Rice and biofragrance products and sustainable ingredients; the Company's reliance on third parties in connection with its development activities and for commercialization; challenges associated with the Company's ability to effectively license its productivity traits and sustainable ingredient products; the risk that farmers do not recognize the value in germplasm containing the Company's traits or that farmers and processors fail to work effectively with crops containing the Company's traits; delays or disruptions in the Company's platform or trait product development efforts; the inability to identify partners to fund the Company's non-Rice productivity trait portfolio; challenges that arise in respect of the Company's production of high-quality plants and seeds cost effectively on a large scale; the Company's dependence on distributions from Cibus Global to pay taxes and cover its corporate and overhead expenses; regulatory developments that disfavor or impose significant burdens on gene editing processes or products; delays and uncertainties regarding regulatory developments in the European Union; the Company's ability to achieve commercial success; commodity prices and other market risks facing the agricultural sector; technological developments that could render the Company's technologies obsolete; impacts of the Company's headcount reductions and other cost reduction measures, which may include operational and strategic challenges, and the potential for additional cost reduction measures; changes in macroeconomic and market conditions, including inflation, supply chain constraints, and rising interest rates, and economic volatility and uncertainty arising from dynamic trade policies, including tariffs and retaliatory tariffs, and market reactions to such policies; dislocations in the capital markets and challenges in accessing liquidity and the impact of such liquidity challenges on the Company's ability to execute on its business plan; the Company's assessment of the period of time through which its financial resources will be adequate to support operations; and the risks and uncertainties described in "Item 1A. Risk Factors," in the Company's Annual Report on Form 10-K, which was filed with the SEC on March 17, 2026, or as they may be updated or supplemented from time-to-time in the Company's subsequent reports on Forms 10-Q and 8-K filed with the SEC. The foregoing factors should be considered an integral part of "Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations." Investors are cautioned not to place undue reliance on any forward-looking statements.

Any forward-looking statements made by the Company in this Quarterly Report on Form 10-Q are based only on currently available information and speak only as of the date hereof. Except as otherwise required by securities and other applicable laws, the Company does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change.

 **Market Data** 

This Quarterly Report on Form 10-Q contains market data and industry statistics and forecasts that are based on independent industry publications, other publicly available information, and the Company's internal sources and estimates (including, its knowledge of, and experience to date in, the potential markets for its products). Although the Company believes that third party sources are reliable, it does not guarantee the accuracy or completeness of the information extracted from these sources, and the Company has not independently verified such information. Similarly, while the Company believes its management estimates to be reasonable, they have not been verified by any independent sources. The market and industry data and estimates presented in this Quarterly Report involve risks and uncertainties and are subject to change based on various factors, including those discussed in the section entitled "Item 1A. Risk Factors" in the Annual Report and other subsequent reports on Forms 10-Q and 8-K filed with the SEC. Forecasts and other forward-looking estimates about the Company's industry or performance within its industry are subject to the risks and uncertainties regarding forward-looking statements described under the caption "Cautionary Note Regarding Forward-Looking Statements." Accordingly, results could differ materially from those expressed in the estimates made by the independent parties and by the Company, and investors should not place undue reliance on this information.

**Website Disclosure** 

The Company uses its website (www.cibus.com), its corporate X account (formerly Twitter) (@CibusGlobal), and its corporate LinkedIn account (https://www.linkedin.com/company/cibus-global) as routine channels of distribution of company information, including press releases, analyst presentations, and supplemental financial information, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor its website and its corporate X and LinkedIn accounts in addition to following press releases, filings with the SEC, and public conference calls and webcasts.

Additionally, the Company provides notifications of announcements as part of its website. Investors and others can receive notifications of new press releases posted on the Company's website by signing up for email alerts.

None of the information provided on the Company's website, in its press releases or public conference calls and webcasts, or through social media is incorporated into, or deemed to be a part of, this Quarterly Report on Form 10-Q or in any other report or document it files with the SEC unless such document specifically states otherwise, and any references to its website or its corporate X and LinkedIn accounts are intended to be inactive textual references only.

**Implications of Being a Smaller Reporting Company**

Cibus is a "smaller reporting company" as defined in the Exchange Act. Cibus may continue to be a smaller reporting company even though it no longer qualifies as an "emerging growth company." As a smaller reporting company, Cibus is exempt from the auditor attestation requirements of the Sarbanes-Oxley Act of 2002 and may also take advantage of certain scaled disclosure accommodations. Cibus will remain a smaller reporting company until the fiscal year following the determination that its common stock held by non-

------

affiliates is $250 million or more (measured on the last business day of Cibus' second fiscal quarter) or Cibus' annual revenues are $100 million or more during the most recently completed fiscal year and Cibus' common stock held by non-affiliates is $700 million or more (measured on the last business day of Cibus' second fiscal quarter).

------

**PART I. FINANCIAL INFORMATION** 

**Item 1. Condensed Consolidated Financial Statements** 

**CIBUS, INC.** 

**CONDENSED CONSOLIDATED BALANCE SHEETS** 

**(Unaudited and in Thousands, Except Par Value and Share Amounts)** 

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $**30325** | $9923 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | **1703** | 503 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | **1041** | 1643 |
| Total current assets | **33069** | 12069 |
| Property, plant, and equipment, net | **5642** | 6300 |
| Operating lease right-of-use assets | **20927** | 21557 |
| Intangible assets, net | **31224** | 31679 |
| Goodwill | **232516** | 232516 |
| Other non-current assets | **824** | 926 |
| **Total assets** | $**324202** | $305047 |
| **Liabilities and stockholders' equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $**5410** | $8070 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | **2027** | 1946 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued compensation | **3011** | 3061 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | **449** | 536 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of notes payable | **194** | 435 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of operating lease obligations | **2764** | 2731 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class A common stock warrants | **89** | 79 |
| Total current liabilities | **13944** | 16858 |
| Notes payable, net of current portion | **73** | 93 |
| Operating lease obligations, net of current portion | **29076** | 29783 |
| Royalty liability - related parties | **244044** | 234923 |
| Other non-current liabilities | **1585** | 1561 |
| **Total liabilities** | **288722** | 283218 |
| Commitments and contingencies (See Note 8) |  |  |
| **Stockholders' equity:** |  |  |
| Class A common stock, $0.0001 par value; 210,000,000 shares authorized; 76,571,627 shares issued and 76,283,095 shares outstanding as of March 31, 2026, and 54,604,232 shares issued and 54,325,852 shares outstanding as of December 31, 2025 | **13** | 11 |
| Class B common stock, $0.0001 par value; 90,000,000 shares authorized; no shares issued and outstanding as of March 31, 2026, and December 31, 2025 | **—** |  |
| Additional paid-in capital | **917136** | 882171 |
| Class A common stock in treasury, at cost; 225,891 shares as of March 31, 2026, and 193,195 shares as of December 31, 2025 | **(2221)** | (2141) |
| Accumulated deficit | **(879473)** | (858251) |
| Accumulated other comprehensive income | **25** | 39 |
| **Total stockholders' equity** | **35480** | 21829 |
| **Total liabilities and stockholders' equity** | $**324202** | $305047 |

---

See accompanying notes to these condensed consolidated financial statements.

------

**CIBUS, INC.** 

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS** 

**(Unaudited and in Thousands, Except Share and Per Share Amounts)** 

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Revenue: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue | $**1681** | $1034 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenue | **1681** | 1034 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development | **8717** | 11799 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general, and administrative | **5084** | 9856 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill impairment | **—** | 20950 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | **13801** | 42605 |
| **Loss from operations** | **(12120)** | (41571) |
| Royalty liability interest expense - related parties | **(9121)** | (8377) |
| Other interest income, net | **28** | 119 |
| Non-operating (expense) income, net | **(2)** | 439 |
| Loss before income taxes | **(21215)** | (49390) |
| Income tax expense | **(7)** | (2) |
| **Net loss** | $**(21222)** | $(49392) |
| Net loss attributable to noncontrolling interest | **—** | (2506) |
| **Net loss attributable to Cibus, Inc. stockholders** | $**(21222)** | $(46886) |
| **Basic and diluted net loss per share of Class A common stock** | $**(0.33)** | $(1.34) |
| **Weighted average shares of Class A common stock outstanding – basic and diluted** | **65202244** | 35052692 |

---

See accompanying notes to these condensed consolidated financial statements.

------

**CIBUS, INC.** 

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS**

**(Unaudited and in Thousands)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Net loss | $**(21222)** | $(49392) |
| Foreign currency translation adjustments | **(14)** | 13 |
| **Comprehensive loss** | **(21236)** | (49379) |
| **Comprehensive loss attributable to noncontrolling interest** | **—** | (2505) |
| **Comprehensive loss attributable to Cibus, Inc. stockholders** | $**(21236)** | $(46874) |

---

See accompanying notes to these condensed consolidated financial statements.

------

**CIBUS, INC.** 

**CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS' EQUITY** 

**(Unaudited and in Thousands, Except Shares Outstanding)** 

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Class A Common Stock** | **Class A Common Stock** | **Class B Common Stock** | **Class B Common Stock** | | | | | |
|<br>**Three Months Ended<br>March 31, 2026** | **Shares** | **Amount** | **Shares** | **Amount** |<br>**Additional<br>Paid-In<br>Capital** |<br>**Shares<br>in<br>Treasury** |<br>**Accumulated<br>Deficit** |<br>**Accumulated Other Comprehensive Income (loss)** |<br>**Total Cibus, Inc. Stockholders' Equity** |
| Balance at December 31, 2025 | 54325852 | $11 |  | $— | $882171 | $(2141) | $(858251) | $39 | $21829 |
| Net loss |  |  |  |  |  |  | (21222) |  | (21222) |
| Stock-based compensation |  |  |  |  | 1571 |  |  |  | 1571 |
| Issuance of common stock upon vesting of restricted stock awards and units | 176531 |  |  |  |  |  |  |  |  |
| Issuance of common stock in registered offering, net | 21813408 | 2 |  |  | 33394 |  |  |  | 33396 |
| Shares withheld for payment of minimum employee taxes withheld upon net share settlement of restricted stock units | (32696) |  |  |  |  | (80) |  |  | (80) |
| Foreign currency translation adjustments |  |  |  |  |  |  |  | (14) | (14) |
| **Balance at March 31, 2026** | **76283095** | $**13** | **—** | $**—** | $**917136** | $**(2221)** | $**(879473)** | $**25** | $**35480** |

---

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | | **Class A Common Stock** | **Class A Common Stock** | **Class B Common Stock** | **Class B Common Stock** | | | | | | | |
|<br>**Three Months Ended<br>March 31, 2025** |<br>**Redeemable Noncontrolling Interest** | **Shares** | **Amount** | **Shares** | **Amount** |<br>**Additional<br>Paid-In<br>Capital** |<br>**Shares<br>in<br>Treasury** |<br>**Accumulated<br>Deficit** |<br>**Accumulated Other Comprehensive Income** |<br>**Total Cibus, Inc. Stockholders' Equity** |<br>**Noncontrolling Interest** |<br>**Total<br>Stockholders'<br>Equity** |
| Balance at December 31, 2024 | $5674 | 27939023 | $9 | 1720929 | $— | $825298 | $(1999) | $(731166) | $15 | $92157 | $— | $92157 |
| Net loss |  |  |  |  |  |  |  | (46886) |  | (46886) | (2506) | (49392) |
| Stock-based compensation |  |  |  |  |  | 2499 |  |  |  | 2499 |  | 2499 |
| Issuance of common stock upon vesting of restricted stock awards and units |  | 75522 |  |  |  |  |  |  |  |  |  |  |
| Issuance of common stock and pre-funded warrants in registered offering, net |  | 4340000 |  |  |  | 21430 |  |  |  | 21430 |  | 21430 |
| Issuance of common stock upon exercise of pre-funded warrants |  | 300000 |  |  |  |  |  |  |  |  |  |  |
| Reclassification of common warrant liability to stockholders' equity |  |  |  |  |  | 1589 |  |  |  | 1589 |  | 1589 |
| Shares withheld for payment of minimum employee taxes withheld upon net share settlement of restricted stock units |  | (5363) |  |  |  |  | (13) |  |  | (13) |  | (13) |
| Reclassification of redeemable noncontrolling interest | (5674) |  |  |  |  |  |  |  |  |  | 5674 | 5674 |
| Change in noncontrolling interest including issuance of common stock upon exchange of common units |  | 8556 |  | (8556) |  | (514) |  |  |  | (514) | 514 |  |
| Foreign currency translation adjustments |  |  |  |  |  |  |  |  | 12 | 12 | 1 | 13 |
| Balance at March 31, 2025 | $— | 32657738 | $9 | 1712373 | $— | $850302 | $(2012) | $(778052) | $27 | $70274 | $3683 | $73957 |

---

See accompanying notes to these condensed consolidated financial statements.

------

**CIBUS, INC.** 

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS** 

**(Unaudited and in Thousands)** 

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **Operating activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss | $**(21222)** | $(49392) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalty liability interest expense - related parties | **9121** | 8377 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill impairment | **—** | 20950 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | **1197** | 1634 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | **1571** | 2499 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on disposal of assets, net | **4** | 80 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of liability classified Class A common stock warrants | **10** | (462) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | **(4)** | 21 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | **(1200)** | 91 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | **591** | 309 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | **(1288)** | 995 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | **(176)** | 3135 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued compensation | **(57)** | (745) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | **(89)** | (71) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Right-of-use assets and lease obligations, net | **(44)** | 688 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets and liabilities, net | **100** | 64 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash used in operating activities** | **(11486)** | (11827) |
| **Investing activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sales of property, plant, and equipment | **43** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of property, plant, and equipment | **(115)** | (291) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash used in investing activities** | **(72)** | (291) |
| **Financing activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuances of securities | **37255** | 22599 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Costs incurred related to issuances of securities | **(4950)** | (1169) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment of taxes related to restricted stock units withheld from employees | **(80)** | (13) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Repayments of notes payable | **(261)** | (148) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by financing activities** | **31964** | 21269 |
| Effect of exchange rate changes on cash and cash equivalents | **(4)** | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net increase in cash and cash equivalents | **20402** | 9154 |
| Cash and cash equivalents – beginning of period | **9923** | 14433 |
| **Cash and cash equivalents – end of period** | $**30325** | $23587 |

---

See accompanying notes to these condensed consolidated financial statements.

------

**CIBUS, INC.** 

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS** 

**1. NATURE OF BUSINESS & SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *Nature of Business and Organization*** Cibus, Inc. (Cibus or the Company) carries on its business through Cibus Global, LLC (Cibus Global) and its subsidiaries. Cibus Global is a plant trait company using gene editing technologies to develop and license gene edited plant traits that improve farming productivity or produce renewable low carbon plant products. Cibus' primary business is the development of plant traits for some of the world's major agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. As the Company is still developing its technology and products, it has not yet begun earning royalty revenues. Cibus Global, a Delaware limited liability company, was formed on May 10, 2019. Immediately prior to the effective date of this formation, Cibus Global was organized as a British Virgin Islands company (Cibus Global, Ltd.), which was formed on September 11, 2008.

The Company was organized in an "Up-C" structure, and the Company's only material asset consists of common membership units of Cibus Global (Common Units). The Company's amended and restated certificate of incorporation designates two classes of the Company's common stock: (i) Class A Common Stock, par value $0.0001 per share (the Class A Common Stock), which shares have full voting and economic rights, and (ii) Class B Common Stock, par value $0.0001 per share (the Class B Common Stock), which shares have full voting, but no economic rights. For holders of Class B Common Stock, each share of Class B Common Stock was paired with a Common Unit (collectively, an Up-C Unit). As of December 31, 2025, there were no remaining Common Unit holders of the noncontrolling interest of Cibus Global and 100 percent of the Common Units of Cibus Global are held by Cibus.

***Basis of Presentation*** The unaudited condensed consolidated financial statements of Cibus, Inc. have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP or GAAP) for interim financial information and the rules and regulations of the Securities and Exchange Commission (SEC) applicable to interim financial statements and has included the accounts of Cibus and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the Company's opinion, the accompanying condensed consolidated financial statements reflect all adjustments necessary for a fair statement of its statements of financial position, results of operations, and cash flows for the periods presented but they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Except as otherwise disclosed herein, these adjustments consist of normal recurring items. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole or any other interim period.

For further information, refer to the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026 (Annual Report). The accompanying condensed consolidated balance sheet as of December 31, 2025, was derived from the audited consolidated financial statements. This Quarterly Report on Form 10-Q should be read in conjunction with the Company's consolidated financial statements and notes thereto included in the Annual Report.

***Going Concern***

The Company has incurred losses since its inception. The Company's net loss was $21.2 million and cash used in operating activities was $11.5 million for the three months ended March 31, 2026. The Company's primary source of liquidity is its cash and cash equivalents, with additional capital resources accessible, subject to market conditions and other factors, from the capital markets, including through offerings of common stock or other securities.

As of March 31, 2026, the Company had $30.3 million of cash and cash equivalents and $13.9 million of current liabilities.

The Company anticipates that it will continue to generate losses for the next several years. Over the longer term and until the Company can generate cash flows sufficient to support its operating capital requirements, it expects to finance a portion of future cash needs through (i) cash on hand, (ii) commercialization activities, which may result in various types of revenue streams from future product development agreements and technology licenses, including upfront and milestone payments, annual license fees, and royalties, (iii) government or other third party funding, (iv) public or private equity or debt financings (which may include a future at-the-market financing facility or other continuous offering facility), or (v) a combination of the foregoing.

In underwritten public offerings in January 2026 (January 2026 Follow-On Offering) and in March 2026 (March 2026 Follow-On Offering), the Company received net proceeds of approximately $19.8 million and $13.6 million, respectively, after deducting approximately $2.5 million and $1.4 million, respectively, for underwriting discounts and commissions and certain other offering expenses payable by the Company.

------

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. Management will need to raise additional capital to support its business plans to continue as a going concern within one year after the date that these financial statements are issued. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

On March 12, 2026, in furtherance of the Company's Board-approved streamlining efforts and in addition to actions taken by the Company in prior years, the Company conducted an additional reduction in workforce of 15 full-time employees, effective as of March 13, 2026. The Company incurred approximately $0.4 million of one-time cash expense in the first quarter of 2026, of which approximately $0.3 million was related to accrued vacation and paid in the first quarter of 2026 and approximately $0.1 million was related to one-time severance expense and will be paid in the second quarter of 2026. In addition, the Company incurred one-time non-cash stock compensation expense of approximately $0.1 million related to accelerated stock awards in the first quarter of 2026, and it will additionally incur approximately $0.1 million in the second quarter of 2026. These expenses were, or will be, recorded within operating expenses in the accompanying condensed consolidated statements of operations. The Company will incur and pay approximately $0.1 million of one-time cash expense related to shares withheld for payment of minimum employee taxes withheld upon net share settlement of restricted stock units in the second quarter of 2026, which will be recorded within class A common stock in treasury, at cost in the accompanying condensed consolidated balance sheets.

These cost reduction initiatives alone will not be sufficient to forestall a cash deficit. If the Company is unable to raise additional capital in a sufficient amount or on acceptable terms, the Company may have to implement additional, more stringent cost reduction measures to manage liquidity, and the Company may have to significantly delay, scale back, or cease operations, in part or in full. If the Company raises additional funds through the issuance of additional debt or equity securities, including as part of a strategic alternative, it could result in substantial dilution to its existing stockholders and increased fixed payment obligations, and these securities may have rights senior to those of the Company's shares of common stock. These factors raise substantial doubt about the Company's ability to continue as a going concern within one year from the issuance of these condensed consolidated financial statements. Any of these events could significantly impact the Company's business, financial condition, and prospects.

***Use of Estimates***

The preparation of the Company's condensed consolidated financial statements and related disclosures in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company's historical experience, knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Key estimates made by the Company include revenue recognition, useful lives and impairment of long-lived assets, valuation of equity-based awards and related equity-based compensation expense, valuation of intangible assets, valuation allowances on deferred tax assets, the assumptions underlying the determination of the estimated incremental borrowing rate for the determination of the Company's operating leases, valuation of warrant liabilities, and the valuation of the Royalty Liability (which refers to the Company's future royalty payment obligations that the Company undertook to provide to certain investors, including related parties, in exchange for certain warrants that these investors acquired in financing transactions in November 2013 and December 2014 and subsequently surrendered to Cibus Global).

***Contract Assets and Liabilities*** Contract assets primarily include amounts related to contractual rights to consideration for completed performance not yet invoiced. The Company recognized $0.1 million in contract assets as of March 31, 2026. There was $0.2 million in contract assets as of December 31, 2025, which are included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets.The Company records contract liabilities when cash payments are received or due in advance of performance, primarily related to advances of upfront and milestone payments from contract research and collaboration agreements. Contract liabilities consist of deferred revenue on the accompanying condensed consolidated balance sheets. The Company expects to recognize the amounts included in deferred revenues within one year.

The following table represents the deferred revenue activity for the three months ended March 31, 2026, and 2025:

---

| | | |
|:---|:---|:---|
| **In Thousands** | **2026** | **2025** |
| Balance as of December 31, | $536 | $932 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unearned revenue from cash received during the period | 444 | 802 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue recognized that was included in the balance at the beginning of the period | (531) | (871) |
| Balance as of March 31, | $**449** | $**863** |

---

------

***Net Loss Per Share of Class A Common Stock*** Weighted average shares of Class A Common Stock outstanding excludes unvested Class A Common Stock, which will be treated as outstanding for financial statement presentation purposes only after such awards have vested and, therefore, have ceased to be subject to a risk of forfeiture. Accordingly, unvested shares of Class A Restricted Stock (as defined below) are excluded from the calculation of net loss per share of Class A Common Stock.

See Note 5 for a detailed discussion of pre-funded warrants issued in January 2025 and subsequent exercises. Outstanding pre-funded warrants are considered equity instruments and are reported in stockholders' equity in the Company's consolidated balance sheets. The weighted average shares of Class A Common Stock outstanding includes the shares issuable upon exercise of the pre-funded warrants and are included in the determination of the Company's basic and diluted net loss per share of Class A Common Stock.

For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the common stock equivalent securities would be antidilutive.

The following table shows the computation of basic and diluted net loss per share of Class A Common Stock for the three months ended March 31, 2026, and 2025:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>**In Thousands, Except Share and Per Share Amounts** | **2026** | **2025** |
| Numerator: |  |  |
| &nbsp;&nbsp;Net loss attributable to Cibus, Inc. stockholders | $**(21222)** | $(46886) |
| Denominator: |  |  |
| &nbsp;&nbsp;Weighted average shares of Class A common stock outstanding | **64802244** | 30602692 |
| &nbsp;&nbsp;Effect of pre-funded warrants | **400000** | 4450000 |
| &nbsp;&nbsp;Weighted average shares of Class A common stock outstanding – basic and diluted | **65202244** | 35052692 |
| Basic and diluted net loss per share of Class A common stock | $**(0.33)** | $(1.34) |

---

The Company's potential dilutive securities, which include common stock warrants, unvested restricted stock units, unvested restricted stock awards, and options to purchase Class A Common Stock, have been excluded from the computation of diluted net loss per share of Class A Common Stock as the effect would be antidilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share of Class A Common Stock is the same.

The following potential dilutive securities, presented on an as converted basis, were excluded from the calculation of net loss per share of Class A Common Stock due to their antidilutive effect:

---

| | | |
|:---|:---|:---|
| | **As of March 31,** | **As of March 31,** |
| | **2026** | **2025** |
| Stock options outstanding | **1434633** | 1152764 |
| Unvested restricted stock units | **1171264** | 1074930 |
| Unvested restricted stock awards | **62641** | 192288 |
| Common warrants | **10496523** | 1456523 |
| Total | **13165061** | 3876505 |

---

***Segment Reporting*** Cibus has one operating and reportable segment. The Chief Operating Decision Maker (CODM) is the Interim Chief Executive Officer who manages business activities, assesses performance, and allocates resources on a consolidated basis. For the three months ended March 31, 2026, and 2025, all revenues from the Company's external customers were derived, and all long-lived assets were located, in the United States. The operating segment revenues are derived from customers as a result of Cibus providing research and development (R&D) services to develop plant traits which are specific genetic characteristics in the DNA of a plant's seed.

The CODM utilizes consolidated net loss in assessing performance and allocating resources by comparing net loss against prior periods and the Company's forecast. The measure of segment assets is reported on the condensed consolidated balance sheets as total consolidated assets.

------

Segment financial information, including significant segment expenses, which are regularly provided to the CODM and included in net loss was as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>**In Thousands** | **2026** | **2025** |
| Revenue | $**1681** | $1034 |
| Less: |  |  |
| &nbsp;&nbsp;Personnel expenses | **5788** | 6761 |
| &nbsp;&nbsp;Professional fees | **1324** | 5423 |
| &nbsp;&nbsp;Stock-based compensation | **1571** | 2499 |
| &nbsp;&nbsp;Goodwill impairment | **—** | 20950 |
| &nbsp;&nbsp;Other segment expenses <sup>(1)</sup> | **5118** | 6972 |
| Total operating expenses | **13801** | 42605 |
| Loss from operations | **(12120)** | (41571) |
| Royalty liability interest expense - related parties | **(9121)** | (8377) |
| Other interest income, net | **28** | 119 |
| Non-operating (expense) income, net | **(2)** | 439 |
| Income tax expense | **(7)** | (2) |
| Total segment loss | $**(21222)** | $(49392) |

---

_______________________________________

(1) Other segment expenses are primarily comprised of facilities and asset related expenses such as rent, asset depreciation and amortization, utilities, property taxes, and repairs and maintenance and also include insurance, dues and subscriptions, licenses, lab supplies, product development, and travel.

***Recently Issued Accounting Pronouncements*** From time-to-time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Company's financial position, results of operations, or cash flows upon adoption.

**2. FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE *Financial Instruments Measured at Fair Value and Financial Statement Presentation*** The accounting guidance establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as of the measurement date as follows:

Level 1: Fair values are based on unadjusted quoted prices in active trading markets for identical assets and liabilities.

Level 2: Fair values are based on observable quoted prices other than those in Level 1, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.

Level 3: Fair values are based on at least one significant unobservable input for the asset or liability.

The Company's policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 3 during the three months ended March 31, 2026, and 2025.

------

***Financial Instruments Required to be Carried at Fair Value*** The Company's financial instruments measured at fair value and their respective levels in the fair value hierarchy as of March 31, 2026, and December 31, 2025, were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| | **Fair Value of Liabilities** | **Fair Value of Liabilities** | **Fair Value of Liabilities** | **Fair Value of Liabilities** | **Fair Value of Liabilities** | **Fair Value of Liabilities** | **Fair Value of Liabilities** | **Fair Value of Liabilities** |
|<br>**In Thousands** | **Level 1** | **Level 2** | **Level 3** | **Total** | **Level 1** | **Level 2** | **Level 3** | **Total** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common warrants | $— | $— | $89 | $89 | $— | $— | $79 | $79 |
| Total | $**—** | $**—** | $**89** | $**89** | $— | $— | $79 | $79 |

---

The following table summarizes the common warrants activity for the three months ended March 31, 2026:

---

| | |
|:---|:---|
| **In Thousands** | **Level 3 Fair Value of Liabilities** |
| Balance as of December 31, 2025 | $79 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value | 10 |
| Balance as of March 31, 2026 | $89 |

---

The following table summarizes the common warrants activity for the three months ended March 31, 2025:

---

| | |
|:---|:---|
| **In Thousands** | **Level 3 Fair Value of Liabilities** |
| Balance as of December 31, 2024 | $2268 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reclassified to stockholders' equity | (1589) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value | (462) |
| Balance as of March 31, 2025 | $217 |

---

In January 2025, as a result of contractual amendments with certain holders of common warrants, the Company reclassified the fair value of 1,100,000 common warrants issued in 2024 of $1.6 million from Class A common stock warrants liability to a component of stockholders' equity within additional paid-in capital in the accompanying consolidated balance sheets. The change in fair value of the Class A common stock warrants liability related to these common warrants of $0.3 million between December 31, 2024, and January 24, 2025, is reflected in non-operating (expense) income, net in the Company's consolidated statements of operations for the three months ended March 31, 2025.

The Company estimates the fair value of the liability classified common warrants as of the date of issuance and at the end of every reporting period using a Black-Scholes option pricing model, which requires it to make assumptions regarding future stock price volatility and dividend yield. The Company estimates the risk-free interest rate based on the United States Treasury zero-coupon yield curve for the remaining life of the common warrants. The Company uses its own historical stock price volatility, over the remaining life of the common warrants. The Company does not pay dividends and does not expect to pay dividends in the foreseeable future.

The estimated fair values of the common warrants, and the assumptions used for the Black-Scholes option pricing model were as follows:

---

| | | |
|:---|:---|:---|
| | **As of March 31, 2026** | **As of December 31, 2025** |
| Estimated fair value of common warrants per share | **$0.02 - $0.86** | $0.01 - $0.77 |
| Assumptions: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Risk-free interest rate | **3.7% - 3.8%** | 3.4% - 3.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expected volatility | **113.6% - 114.5%** | 103.8% - 114.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expected term to liquidation (in years) | **1.4 - 3.2** | 1.6 - 3.5 |

---

As of March 31, 2026, and 2025, the Company had no other financial instruments measured at fair value.

------

**3. PROPERTY, PLANT, AND EQUIPMENT, NET**

Property, plant, and equipment, net consists of the following:

---

| | | | |
|:---|:---|:---|:---|
| **In Thousands, except useful life** | **Useful Life<br>(Years)** | **As of March 31, 2026** | **As of December 31, 2025** |
| Property, plant, and equipment, net: |  |  |  |
| Buildings | 10 - 20 | $**900** | $900 |
| Leasehold improvements | shorter of lease term or useful life | **2458** | 2458 |
| Office furniture and equipment | 5 - 10 | **15091** | 15091 |
| Computer equipment and software | 3 - 5 | **4892** | 4737 |
| Assets in progress | N/A | **42** | 155 |
| Total property, plant, and equipment |  | **23383** | 23341 |
| Less accumulated depreciation and amortization |  | **(17741)** | (17041) |
| Total |  | $**5642** | $6300 |

---

Depreciation and amortization expense is as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>**In Thousands** | **2026** | **2025** |
| Depreciation and amortization expense | $**715** | $1152 |

---

**4. GOODWILL AND INTANGIBLE ASSETS *Goodwill*** There was no change to the Company's goodwill during the three months ended March 31, 2026.Goodwill activity is as follows for the three months ended March 31, 2025:

---

| | |
|:---|:---|
| **In Thousands** | **Goodwill** |
| Balance as of December 31, 2024 | $253466 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill impairment | (20950) |
| Balance as of March 31, 2025 | $232516 |

---

During the first quarter of 2025, the Company experienced a triggering event and assessed its goodwill for impairment. The Company considered the decline in its stock price since its last assessment of goodwill and concluded it was more likely than not that its goodwill would be impaired. The Company then performed a quantitative analysis and concluded that its goodwill was impaired. Management makes critical assumptions and estimates in completing impairment assessments of goodwill. The Company utilized the discounted cash flow method to calculate the fair value of the reporting unit. The Company's future cash flow projections include assumptions on variables such as future royalties and operating margins, economic conditions, probability of success, market competition, inflation, and discount rates. In addition, the Company compares the fair value of the reporting unit to the Company's overall market capitalization. The Company utilized its most recent cash flow projections in combination with the Company's stock price as of March 31, 2025, to calculate the fair value of the reporting unit using a long-term growth rate of 3 percent and a discount rate of 47 percent, which are Level 3 fair value measurements. The Company determined its goodwill was impaired by $21.0 million, which is recorded in the accompanying condensed consolidated statements of operations for the three months ended March 31, 2025.

The Company's gross amount of goodwill prior to accumulated impairment losses as of March 31, 2026, and 2025, was $585.3 million. The Company's accumulated goodwill impairment loss as of March 31, 2026, and 2025, was $352.8 million.

A triggering event that could indicate impairment and necessitate an evaluation of goodwill includes, but is not limited to, macroeconomic conditions, industry and market considerations, increases in Cibus' costs, commercial performance relative to strategic initiatives, adverse regulatory developments, or the decline in Cibus' market capitalization.

------

To the extent a triggering event occurs and Cibus concludes that goodwill has become further impaired, Cibus may be required to incur material write-offs relating to such impairment and any such write-offs could have a material impact on the Company's future operating results and financial position.

***Intangible Assets*** Intangible assets as of March 31, 2026, were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **In Thousands** | **Gross Carrying Amount** | **Accumulated Amortization** | **Intangible Assets, Net** |
| Developed technology | $14148 | $(2005) | $12143 |
| Trade name | 22230 | (3149) | 19081 |
| Total | $**36378** | $**(5154)** | $**31224** |

---

Intangible assets as of December 31, 2025, were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **In Thousands** | **Gross Carrying Amount** | **Accumulated Amortization** | **Intangible Assets, Net** |
| Developed technology | $14148 | $(1828) | $12320 |
| Trade name | 22230 | (2871) | 19359 |
| Total | $36378 | $(4699) | $31679 |

---

Total amortization expense is as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>**In Thousands** | **2026** | **2025** |
| Amortization expense | $**455** | $455 |

---

As of March 31, 2026, future amortization expense is estimated as follows:

---

| | |
|:---|:---|
| **In Thousands** | **Amortization Expense** |
| Remainder of 2026 | $1364 |
| 2027 | 1819 |
| 2028 | 1819 |
| 2029 | 1819 |
| 2030 | 1819 |
| 2031 | 1819 |
| Thereafter | 20765 |
| &nbsp;&nbsp;Total future amortization expense | $**31224** |

---

**5. STOCKHOLDERS' EQUITY** Pursuant to the Company's amended and restated certificate of incorporation, the Company is authorized to issue up to 310,000,000 shares, consisting of (i) up to 300,000,000 shares of common stock, par value $0.0001 per share, divided into (A) up to 210,000,000 shares of Class A Common Stock and (B) up to 90,000,000 shares of Class B Common Stock and (ii) up to 10,000,000 shares of preferred stock, par value $0.0001 per share.

------

Warrant transactions for the three months ended March 31, 2026, were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Pre-Funded Warrants** | **Weighted Average** <br>**Exercise**<br>**Price Per Share** | **Common Warrants** | **Weighted Average** <br>**Exercise**<br>**Price Per Share** |
| Outstanding as of December 31, 2025 | 400000 | $0.0001 | 10496523 | $3.58 |
| Issued |  |  |  |  |
| Forfeited/canceled |  |  |  |  |
| Exercised |  |  |  |  |
| **Outstanding as of March 31, 2026** | **400000** | $**0.0001** | **10496523** | $**3.58** |
| **Exercisable as of March 31, 2026** | **400000** | $**0.0001** | **10496523** | $**3.58** |

---

 ***January 2026 SEC-Registered Public Offering***In the January 2026 Follow-On Offering, the Company issued 14,836,664 shares of its Class A Common Stock including 333,333 shares issued to Mr. Riggs. The offering price for each share of Class A Common Stock was $1.50. The Company received net proceeds related to the January 2026 Follow-On Offering of approximately $19.8 million after deducting approximately $2.5 million for underwriting discounts and commissions and certain other offering expenses payable by the Company.

***March 2026 SEC-Registered Public Offering*** In the March 2026 Follow-On Offering, the Company issued 6,976,744 shares of its Class A Common Stock. The offering price for each share of Class A Common Stock was $2.15. The Company received net proceeds related to the March 2026 Follow-On Offering of approximately $13.6 million after deducting approximately $1.4 million for underwriting discounts and commissions and certain other offering expenses payable by the Company. ***Class A Common Stock*** Shares of Class A Common Stock have full voting and economic rights. Unvested shares of Class A Restricted Stock, which were issued as equity compensation to certain of the Company's employees and executive officers, carry all voting, dividend, distribution, and other rights as apply to shares of Class A Common Stock generally, except that (i) shares of Class A Restricted Stock are subject to transfer restrictions and (ii) dividends and distributions are held by the Company until vesting of the underlying shares of Class A Restricted Stock and remain subject to the same forfeiture provisions as such shares.

***Class A Restricted Stock*** Restricted shares of Class A Common Stock (Class A Restricted Stock) are considered to be legally issued and outstanding as of the date of grant, notwithstanding that these shares remain subject to risk of forfeiture if the vesting conditions for such shares are not met. For financial statement presentation purposes, Class A Restricted Stock is treated as issued, but will only be treated as outstanding after such awards have vested and, therefore, have ceased to be subject to a risk of forfeiture. Accordingly, unvested shares of Class A Restricted Stock are excluded from the calculation of basic net loss per share of Class A Common Stock.

***Class B Common Stock***

Shares of Class B Common Stock have full voting rights. Shares of Class B Common Stock have no economic rights and do not participate in dividends or undistributed earnings. However, holders of Class B Common Stock hold a corresponding number of economic, non-voting Common Units through which they would receive *pro rata* distributions from Cibus Global. No shares of Class B Common Stock were outstanding as of March 31, 2026.

***Cibus Global Common Units***

The Company's exchange agreement set forth the terms and conditions upon which holders of Up-C Units, comprising an equal number of shares of Class B Common Stock and Cibus Global Common Units, could exchange such Up-C Units for shares of Class A Common Stock. The Up-C Units were generally exchangeable for shares of Class A Common Stock on a one-for-one basis, subject to certain restrictions. The holders of Up-C Units' ownership of Common Units represented the noncontrolling interest.

Up-C Unit exchanges during the three months ended March 31, 2026, and 2025 were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Up-C Units exchanged by holders for Class A Common Stock | **—** | 8556 |

---

------

As of March 31, 2026, there were 76,283,095 Cibus Global Common Units outstanding. Of the 76,283,095 Cibus Global Common Units outstanding, all are held by Cibus, Inc. as there are no remaining holders of Up-C Units.

***Preferred Stock*** Pursuant to the amended and restated certificate of incorporation, the Company is authorized to issue 10,000,000 shares of preferred stock, par value $0.0001 per share. As of March 31, 2026, the Company has not issued any preferred stock.

**6. STOCK-BASED COMPENSATION** The Company uses broad-based stock plans to attract and retain highly qualified officers and employees and to help ensure that management's interests are aligned with those of its shareholders. The Company has also granted equity-based awards to directors, non-employees, and certain employees of Cellectis, formerly the Company's largest shareholder and parent company prior to the completion of the merger with Cibus Global.

In December 2014, the Company adopted the Calyxt, Inc. Equity Incentive Plan (2014 Plan), which allowed for the grant of stock options, and in June 2017, it adopted the Calyxt, Inc. 2017 Omnibus Plan (2017 Plan), which allowed for the grant of stock options, restricted stock units (RSUs), performance stock units (PSUs), and other types of equity awards. The name of the 2017 Plan was amended to reflect the name change of the Company to Cibus, Inc.

As of March 31, 2026, 2,951,224 shares were available for grant in the form of stock options, restricted stock, RSUs, and PSUs under the 2017 Plan. In March 2026, the Board authorized an additional 4,080,827 shares for issuance pursuant to the 2017 Plan, which shares may be issued pursuant to the 2017 Plan upon registration with the SEC. Stock-based awards currently outstanding also include awards granted under the 2014 Plan. No further awards are available for grant or will be granted under the 2014 Plan.

***Stock Options*** The weighted average fair value of stock options granted, and the assumptions used for the Black-Scholes option pricing model were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2026** | **2025** | **2025** |
| Weighted average fair value of stock options granted | **$** | **1.84** | $| 1.83 |
| Assumptions: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Risk-free interest rate | **3.6%** | **3.6%** | 4.1% | 4.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expected volatility | **109.7%** | **109.7%** | 106.2% - 106.6% | 106.2% - 106.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expected term (in years) | **5.0** | **5.0** | 6.0 | 6.0 |

---

Option strike prices are set at 100 percent or more of the closing share price on the date of grant and generally vest over three to four years following the grant date. Options generally expire 10 years after the date of grant.

Information on stock option activity is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Options** <br>**Exercisable** | **Weighted Average**<br>**Exercise** <br>**Price Per** <br>**Share**  | **Options** <br>**Outstanding**  | **Weighted Average** <br>**Exercise** <br>**Price Per** <br>**Share**  |
| Balance as of December 31, 2025 | 382808 | $99.71 | 1358797 | $30.25 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Granted |  |  | 81141 | 2.30 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vested | 151130 | 2.60 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercised |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expired | (5305) | 352.41 | (5305) | 352.41 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forfeited |  |  |  |  |
| **Balance as of March 31, 2026** | **528633** | $**69.41** | **1434633** | $**27.48** |

---

------

Stock-based compensation expense related to stock option awards is as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>**In Thousands** | **2026** | **2025** |
| Stock-based compensation expense | $**455** | $232 |

---

As of March 31, 2026, options outstanding had a $0.1 million aggregate intrinsic value and a weighted average remaining contractual term of 8.2 years. As of March 31, 2026, options exercisable had no aggregate intrinsic value and a weighted average remaining contractual term of 7.0 years.

As of March 31, 2026, unrecognized compensation expense related to non-vested stock options was $1.5 million which has a weighted average remaining recognition period of 2.2 years.

 ***Restricted Stock Awards*** The Company granted awards of Class A Restricted Stock (RSAs), in connection with its merger with Cibus Global, to Cibus Global members who held unvested restricted profits interest units. The RSAs will continue to vest following their original vesting schedules over the remaining life of the awards which is generally two months to four years after the date of grant.

Information on RSA activity is as follows:

---

| | | |
|:---|:---|:---|
| | **Restricted Stock** <br>**Awards**  | **Weighted Average Grant** <br>**Date Fair Value** |
| Unvested balance as of December 31, 2025 | 85185 | $31.50 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Granted |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vested | (21235) | 31.50 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forfeited | (1309) | 31.50 |
| **Unvested balance as of March 31, 2026** | **62641** | $**31.50** |

---

The total fair value of RSAs that vested is as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>**In Thousands** | **2026** | **2025** |
| Fair value of shares vested | $**54** | $131 |

---

There were no RSAs granted during the three months ended March 31, 2026, or 2025.

Stock-based compensation expense related to RSAs is as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>**In Thousands** | **2026** | **2025** |
| Stock-based compensation expense | $**619** | $1840 |

---

As of March 31, 2026, unrecognized compensation expense related to RSAs was $1.8 million which has a weighted average remaining recognition period of 0.9 years.

***Restricted Stock Units*** The Company grants RSUs which generally vest over four years after the date of grant. Upon vesting, the RSUs are settled as shares of Class A Common Stock.

------

Information on RSU activity is as follows:

---

| | | |
|:---|:---|:---|
| | **Restricted Stock** <br>**Units**  | **Weighted Average Grant** <br>**Date Fair Value** |
| Unvested balance as of December 31, 2025 | 1359207 | $3.73 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Granted |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vested | (155296) | 5.01 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forfeited | (32647) | 2.75 |
| **Unvested balance as of March 31, 2026** | **1171264** | $**3.59** |

---

The total fair value of RSUs that vested is as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>**In Thousands** | **2026** | **2025** |
| Fair value of shares vested | $**400** | $34 |

---

There were no RSUs granted during the three months ended March 31, 2026, and the weighted average grant date fair value of RSUs granted during the three months ended March 31, 2025, was $2.53.

Stock-based compensation expense related to RSUs is as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>**In Thousands** | **2026** | **2025** |
| Stock-based compensation expense | $**497** | $427 |

---

As of March 31, 2026, unrecognized compensation expense related to RSUs was $3.3 million which has a weighted average remaining recognition period of 2.6 years.

Certain consolidated statement of operations amounts were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>**In Thousands** | **2026** | **2025** |
| Stock-based compensation expense: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development | $**528** | $968 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general, and administrative | **1043** | 1531 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $**1571** | $2499 |

---

**7. INCOME TAXES** The Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of the deferred tax assets. The Company has established a full valuation allowance for deferred tax assets due to the uncertainty that enough taxable income will be generated in the taxing jurisdiction to utilize the assets. Therefore, the Company has not reflected any benefit of such deferred tax assets in the accompanying condensed consolidated financial statements.

The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates, and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Current income taxes are recorded based on statutory obligations for the current operating period for the foreign jurisdictions in which the Company has operations. As such, the Company recorded a nominal income tax provision for foreign jurisdictions for the three months ended March 31, 2026. No current income tax provision has been recorded for United States operations for the three months ended March 31, 2026, due to the Company's history of net operating losses, and the maintenance of a full valuation allowance against its deferred tax assets.

The Company has recorded a full valuation allowance against its net deferred tax assets as the realizability of the tax benefit is not at the more likely than not threshold. Since the benefit has not been recorded, the Company determined that the liability associated with the

------

Company's Tax Receivables Agreement (TRA), dated May 31, 2023, is not probable and therefore no TRA liability has been recorded as of March 31, 2026.

As of March 31, 2026, there were no material changes to what the Company disclosed regarding tax uncertainties or penalties as of December 31, 2025.

**8. LEASES, COMMITMENTS, AND CONTINGENCIES** 

***Leases***

The Company's financing lease right-of-use (ROU) asset is included in other non-current assets in the condensed consolidated balance sheets.

The components of lease expense were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>**In Thousands** | **2026** | **2025** |
| Finance lease costs | $**27** | $30 |
| Operating lease costs | **1220** | 1527 |
| Variable lease costs | **771** | 1008 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $**2018** | $2565 |

---

Operating lease costs for short-term leases was not material for the three months ended March 31, 2026, or 2025.

Supplemental cash flow information related to leases was as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>**In Thousands** | **2026** | **2025** |
| Cash paid for amounts included in the measurement of lease liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating cash flows (operating leases) | $**1264** | $495 |

---

Supplemental balance sheet information related to leases was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **As of March 31, 2026** | **As of March 31, 2026** | **As of December 31, 2025** | **As of December 31, 2025** |
| | **Operating** | **Financing** | **Operating** | **Financing** |
| Weighted average remaining lease term (years) | **8.9** | **0.4** | 9.1 | 0.7 |
| Weighted average discount rate | **7.5%** | **10.6%** | 7.5% | 10.6% |

---

As of March 31, 2026, future minimum payments under operating leases were as follows:

---

| | |
|:---|:---|
| **In Thousands** | **Operating**  |
| Remainder of 2026 | $3781 |
| 2027 | 5045 |
| 2028 | 5081 |
| 2029 | 4905 |
| 2030 | 5004 |
| Thereafter | 20312 |
|  | 44128 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: interest | (12288) |
| Total | $**31840** |
| Current portion | $**2764** |
| Noncurrent portion | $**29076** |

---

------

***Litigation and Claims*** From time-to-time, the Company may be involved in legal proceedings arising in the ordinary course of business. The Company is not a party to any material pending legal proceedings as of March 31, 2026.

**9. ROYALTY LIABILITY - RELATED PARTIES**

As of March 31, 2026, the Royalty Liability reflected an effective yield of 16.5 percent and the amount of aggregated, but unpaid, Royalty Payments is $0.6 million. As of December 31, 2025, the Royalty Liability reflected an effective yield of 16.5 percent.

The following table summarizes the Royalty Liability activity for the three months ended March 31, 2026, and 2025:

---

| | | |
|:---|:---|:---|
| **In Thousands** | **2026** | **2025** |
| Balance as of December 31, | $234923 | $199442 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense recognized | 9121 | 8377 |
| Balance as of March 31, | $**244044** | $207819 |

---

**10. SUPPLEMENTAL INFORMATION** 

Supplemental consolidated statement of cash flows information is as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>**In Thousands** | **2026** | **2025** |
| Interest paid | $**11** | $19 |

---

Non-cash transactions not reported in the condensed consolidated statements of cash flows is as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>**In Thousands** | **2026** | **2025** |
| Property, plant, and equipment acquired through assuming liabilities | $**—** | $27 |
| Unpaid stock offering costs included in accounts payable | $**217** | $— |
| Unpaid stock offering costs included in accrued expenses | $**204** | $— |
| Class A common stock warrants reclassification from liability to stockholders' equity | $**—** | $1589 |

---

**11. COLLABORATION AGREEMENT** Cibus and Procter & Gamble (P&G), a leading multi-national consumer product company, are parties to a collaboration agreement (P&G agreement) under which P&G is partially funding and/or supporting a multi-year program to develop low carbon ingredients or materials aimed at reducing impacts on the environment during production, use, or disposal. As of March 31, 2026, the Company had $0.4 million of deferred revenue from R&D activities under the P&G agreement. The Company has determined the P&G agreement should be accounted for under Topic 606.

Revenue recognized in the condensed consolidated statements of operations related to the collaboration agreement is as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **In Thousands** | **2026** | **2025** |
| Collaboration agreement revenue recognized | $**1436** | $869 |

---

------

As of March 31, 2026, the cumulative amount of consideration allocated to the performance obligation and revenue recognized under the P&G agreement is $8.8 million.

------

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.** 

*The following discussion and analysis of the Company's financial condition and results of operations should be read together with its condensed consolidated financial statements and related notes, which are included elsewhere in this Quarterly Report on Form 10-Q and with its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (SEC) on March 17, 2026 (Annual Report), including the Consolidated Financial Statements and Notes incorporated therein.*

**OVERVIEW AND BUSINESS UPDATE** Cibus is a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits, which are specific genetic characteristics in the DNA of a plant's seed. These plant traits, or characteristics, influence how a resulting plant functions and/or interacts with its environment.

Cibus' primary business is the development of plant traits for some of the world's major agricultural crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. These plant traits can be licensed to global seed companies where the licensee company will include these traits in their seed products and for that Cibus will receive an annual royalty for seed sold, usually structured as a per-acre planted royalty. This is not a new business model as many companies have developed traits that have been added to seed products and have garnered significant royalties for their developers over many years. Importantly, farmers are well acquainted with the value of these seeds with traits. Cibus' initial focus is on productivity traits, which can be associated with improving crop yields in the face of challenges such as weeds, pests, and diseases, can address environmental challenges with an overall reduction in the use of chemicals like fungicides, insecticides, or fertilizers, or can make crops more adaptable to environmental factors such as heat and drought in the face of climate change.

In the near term, Cibus' priority pipeline program centers on Rice herbicide tolerance (HT) traits and sustainable ingredients opportunities. The Company also retains the rights to the remainder of its productivity trait portfolio and will opportunistically pursue partner-funded projects in such traits.

Cibus has experienced continued momentum across its priority programs during the first quarter of 2026. The Company continues to work with its global seed company partners to change the scale and speed of breeding. Cibus' Rice HT program is advancing on multiple fronts, including meaningful progress toward commercialization with the Company's Latin American seed partners. With respect to Cibus' Rice HT program, the Company continues a targeted initial launch in Latin America beginning in 2027, with expansion planned into the United States in 2029. The decision to delay the United States target launch date from the previous 2028 target relates to aspects of the registration process for the Rice herbicide of Cibus' chemistry partner, Albaugh, which are behind initial timing estimates.

With respect to Cibus' sustainable ingredients program, Cibus executed an amendment to its current contract with its sustainable ingredients partner, which enables additional partner-funded research and development (R&D) activities.

Positive regulatory momentum continued during the first quarter of 2026. In April, the Council of the European Union confirmed the agreed legislative text regulating New Genomic Techniques (NGTs) with that text now before the European Parliament for a plenary vote planned for an upcoming session.

The Company has incurred net losses since its inception. As of March 31, 2026, the Company had an accumulated deficit of $879.5 million. The Company's net loss was $21.2 million for the three months ended March 31, 2026. As Cibus continues to develop its pipeline of productivity traits and as a result of its limited commercial activities, Cibus expects to continue to incur significant expenses and operating losses for the next several years. Those expenses and losses may fluctuate significantly from quarter-to-quarter and year-to-year.

------

**RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 2026, COMPARED TO THE THREE MONTHS ENDED MARCH 31, 2025**

A summary of the Company's results of operations for the three months ended March 31, 2026, and 2025 follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **In Thousands, except per share and percentage values** | **2026** | **2025** | **$ Change**  | **% Change**  |
| **Revenue** | $**1681** | $1034 | $647 | 63% |
| Research and development | **8717** | 11799 | (3082) | (26)% |
| Selling, general, and administrative | **5084** | 9856 | (4772) | (48)% |
| Goodwill impairment | **—** | 20950 | (20950) | (100)% |
| **Loss from operations** | **(12120)** | (41571) | 29451 | 71% |
| Royalty liability interest expense - related parties | **(9121)** | (8377) | (744) | (9)% |
| Other interest income, net | **28** | 119 | (91) | (76)% |
| Non-operating (expense) income, net | **(2)** | 439 | (441) | (100)% |
| Loss before income taxes | **(21215)** | (49390) | 28175 | 57% |
| Income tax expense | **(7)** | (2) | (5) | (250)% |
| **Net loss** | $**(21222)** | $(49392) | $28170 | 57% |
| **Net loss attributable to noncontrolling interest** | **—** | (2506) | 2506 | 100% |
| **Net loss attributable to Cibus, Inc. stockholders** | $**(21222)** | $(46886) | $25664 | 55% |
| **Basic and diluted net loss per share of Class A common stock** | $**(0.33)** | $(1.34) | $1.01 | 75% |

---

***Revenue***

Revenue was $1.7 million in the first quarter of 2026, an increase of $0.6 million from the first quarter of 2025. The increase was driven by amounts earned from collaboration agreements related to contract research for Sustainable Ingredients.

***Research and Development Expense***

R&D expense was $8.7 million in the first quarter of 2026, a decrease of $3.1 million from the first quarter of 2025. The decrease was primarily due to cost reduction initiatives.

***Selling, General, and Administrative Expense***

Selling, general, and administrative (SG&A) expense was $5.1 million in the first quarter of 2026, a decrease of $4.8 million from the first quarter of 2025. The decrease was primarily due to a $3.0 million litigation expense in the first quarter of 2025 as well as cost reduction initiatives.

***Goodwill Impairment***

There was no goodwill impairment in the first quarter of 2026, a decrease of $21.0 million from the first quarter of 2025. The decrease was due to the impairment of goodwill resulting from fair value assessments, based on the decline of the Company's stock price, performed in the first quarter of 2025.

***Royalty Liability Interest Expense - Related Parties*** Royalty liability interest expense - related parties was $9.1 million in the first quarter of 2026, an increase of $0.7 million from the first quarter of 2025. The increase is driven by the recognition of interest expense on the accumulating Royalty Liability balance.

***Other Interest Income, net*** Other interest income, net was nominal in the first quarter of 2026, a decrease of $0.1 million from the first quarter of 2025. The decrease was driven by lower cash balances.

***Non-Operating (Expense) Income, net***

Non-operating (expense) income, net was nominal in the first quarter of 2026, a decrease of $0.4 million in income from the first quarter of 2025. The decrease in income was driven by the fair value adjustment of liability classified common warrants..

------

***Net Loss Attributable to Noncontrolling Interest*** There was no net loss attributable to noncontrolling interest in the first quarter of 2026, a decrease in net loss attributable to noncontrolling interest of $2.5 million from 2025. The decrease in net loss attributable to noncontrolling interest is a result of all Up-C Units being exchanged in 2025, as the amount for the period is based on the percentage of Cibus Global that is not owned by Cibus, Inc.

**LIQUIDITY AND CAPITAL RESOURCES *Liquidity*** The Company's primary source of liquidity is its cash and cash equivalents, with additional capital resources accessible from the capital markets, subject to market conditions and other factors, including limitations that may apply to the Company under applicable Nasdaq regulations.

The Company's liquidity funds its non-discretionary cash requirements and its discretionary spending. The Company has contractual obligations related to recurring business operations, primarily related to lease payments for its corporate and laboratory facilities. The Company's principal discretionary cash spending is for salaries, capital expenditures, short-term working capital payments, and professional and other transaction-related expenses incurred as the Company pursues additional financing. Until the Company is able to obtain additional public or private financing, it currently expects to satisfy its near-term requirements with existing cash on hand.

As of March 31, 2026, the Company had $30.3 million of cash and cash equivalents. Current liabilities were $13.9 million as of March 31, 2026. The Company incurred a net loss of $21.2 million for the three months ended March 31, 2026. As of March 31, 2026, the Company had an accumulated deficit of $879.5 million and expects to continue to incur losses in the future.

***Cash Flows from Operating Activities***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>**In Thousands, except percentage values** | **2026** | **2025** | **$ Change** | **% Change** |
| Net loss | $**(21222)** | $(49392) | $28170 | 57% |
| Royalty liability interest expense - related parties | **9121** | 8377 | 744 | 9% |
| Goodwill impairment | **—** | 20950 | (20950) | (100)% |
| Depreciation and amortization | **1197** | 1634 | (437) | (27)% |
| Stock-based compensation | **1571** | 2499 | (928) | (37)% |
| Loss on disposal of assets, net | **4** | 80 | (76) | (95)% |
| Change in fair value of liability classified Class A common stock warrants | **10** | (462) | 472 | 102% |
| Other | **(4)** | 21 | (25) | (119)% |
| Changes in operating assets and liabilities | **(2163)** | 4466 | (6629) | (148)% |
| Net cash used in operating activities | $**(11486)** | $(11827) | $341 | 3% |

---

Net cash used in operating activities was $11.5 million in the first three months of 2026, a decrease in cash used of $0.3 million from the first three months of 2025. The decrease in cash used is driven by a $3.9 million decrease in net loss, primarily related to an increase of $0.6 million in revenue and cost reduction initiatives including decreases of $1.1 million in professional fees, $1.0 million in personnel and travel related expenses, $0.9 million in facilities and other office expenses, and $0.3 million in lab supplies. The improved net loss is offset by a decrease of $3.6 million from the changes in operating assets and liabilities. The decrease is due to $1.3 million higher accounts receivable, $1.9 million lower accounts payable and accrued expenses, $0.7 million lower right-of-use assets and liabilities due to the end of Nancy Ridge rent abatement, and $0.3 million lower prepaid expenses.

------

***Cash Flows from Investing Activities*** 

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>**In Thousands, except percentage values** | **2026** | **2025** | **$ Change** | **% Change** |
| Proceeds from sales of property, plant, and equipment | $**43** | $— | $43 | NM |
| Purchases of property, plant, and equipment | **(115)** | (291) | 176 | 60% |
| Net cash used in investing activities | $**(72)** | $(291) | $219 | 75% |

---

NM – not meaningful

Net cash used in investing activities was $0.1 million in the first three months of 2026, a decrease of $0.2 million from the first three months of 2025. The decrease in cash used was driven by a decrease in purchases of property, plant, and equipment from the prior year.

***Cash Flows from Financing Activities***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>**In Thousands, except percentage values** | **2026** | **2025** | **$ Change** | **% Change** |
| Proceeds from issuances of securities | $**37255** | $22599 | $14656 | 65% |
| Costs incurred related to issuances of securities | **(4950)** | (1169) | (3781) | (323)% |
| Payment of taxes related to restricted stock units withheld from employees | **(80)** | (13) | (67) | (515)% |
| Repayments of notes payable | **(261)** | (148) | (113) | (76)% |
| Net cash provided by financing activities | $**31964** | $21269 | $10695 | 50% |

---

Net cash provided by financing activities was $32.0 million in the first three months of 2026, an increase of $10.7 million from the first three months of 2025. The increase was primarily due to an increase of $10.9 million of net proceeds from additional capital raised in 2026.

***Capital Resources*** The Company's primary source of liquidity is its cash and cash equivalents, with additional capital resources accessible, subject to market conditions and other factors, including limitations that may apply to the Company under applicable Nasdaq and SEC regulations, from the capital markets, including through stock offerings of common stock or other securities, which may be implemented pursuant to the Company's effective registration statement on Form S-3.

***January 2026 SEC-Registered Public Offering***

In January 2026, the Company issued 14,836,664 shares of its Class A Common Stock including 333,333 shares issued to Mr. Riggs (January 2026 Follow-On Offering). The offering price for each share of Class A Common Stock was $1.50. The Company received net proceeds related to the January 2026 Follow-On Offering of approximately $19.8 million after deducting approximately $2.5 million for underwriting discounts and commissions and certain other offering expenses payable by the Company.

***March 2026 SEC-Registered Public Offering*** In March 2026, the Company issued 6,976,744 shares of its Class A Common Stock (March 2026 Follow-On Offering). The offering price for each share of Class A Common Stock was $2.15. The Company received net proceeds related to the March 2026 Follow-On Offering of approximately $13.6 million after deducting approximately $1.4 million for underwriting discounts and commissions and certain other offering expenses payable by the Company.

***Operating Capital Requirements*** The Company has incurred losses since its inception. The Company's net loss was $21.2 million and cash used in operating activities was $11.5 million for the three months ended March 31, 2026.

As of March 31, 2026, the Company had $30.3 million of cash and cash equivalents. Current liabilities were $13.9 million as of March 31, 2026.

On March 12, 2026, in furtherance of the Company's Board-approved streamlining efforts and in addition to actions taken by the Company in prior years, the Company conducted an additional reduction in workforce of 15 full-time employees, effective as of March 13, 2026. The Company incurred approximately $0.4 million of one-time cash expense in the first quarter of 2026, of which

------

approximately $0.3 million was related to accrued vacation and paid in the first quarter of 2026 and approximately $0.1 million was related to one-time severance expense and will be paid in the second quarter of 2026. In addition, the Company incurred one-time non-cash stock compensation expense of approximately $0.1 million related to accelerated stock awards in the first quarter of 2026, and it will additionally incur approximately $0.1 million in the second quarter of 2026. These expenses were, or will be, recorded within operating expenses in the accompanying condensed consolidated statements of operations. The Company will incur and pay approximately $0.1 million of one-time cash expense related to shares withheld for payment of minimum employee taxes withheld upon net share settlement of restricted stock units in the second quarter of 2026, which will be recorded within class A common stock in treasury, at cost in the accompanying condensed consolidated balance sheets.

In light of these streamlining cost reduction actions, the Company anticipates reducing its annual net cash usage to approximately $30.0 million or less during the course of 2026. The Company anticipates that such efforts will contribute toward improved cash flow and financial stability. The Company is in the process of completing the consolidation of its core operations to San Diego, CA while prioritizing resources toward advancing its Rice programs and completing ongoing non-Rice activities that are not partner-funded, while deferring initiation of new non-partner-funded activities outside of Rice, such as field testing.

The Company has incurred losses since its inception and anticipates that it will continue to generate losses for the next several years. Over the longer term and until the Company can generate cash flows sufficient to support its operating capital requirements, it expects to finance a portion of future cash needs through (i) cash on hand, (ii) commercialization activities, which may result in various types of revenue streams from future product development agreements and technology licenses, including upfront and milestone payments, annual license fees, and royalties, (iii) government or other third party funding, (iv) public or private equity or debt financings (which may include a future at-the-market financing facility or other continuous offering facility), or (v) a combination of the foregoing. However, capital generated by commercialization activities, if any, is expected to be received over a period of time and near-term additional capital may not be available on reasonable terms, if at all. Cibus' Board of Directors continues to evaluate a full range of strategic alternatives to maximize shareholder value.

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

The Company's ability to continue as a going concern will depend on its ability to obtain additional public or private equity or debt financing (which may include a future at-the-market financing facility or other continuous offering facility), obtain government or private grants and other similar types of funding, attain further operating efficiencies, reduce or contain expenditures, and, ultimately, to generate revenue. The Company believes that its cash and cash equivalents as of March 31, 2026, is not sufficient to fund its operations for a period of 12 months or more from the date of this filing. Taking into account the impact of cost saving initiatives implemented through the date of this Quarterly Report on Form 10-Q and without giving effect to potential financing transactions Cibus may pursue, Cibus expects that its existing cash and cash equivalents is sufficient to fund planned operating expenses and capital expenditure requirements into late in the first quarter of 2027. The Company's assessment of the period of time through which its financial resources will be adequate to support its operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. The Company has based this estimate on assumptions that may prove to be wrong. Circumstances and business conditions may change that would require the Company to use its cash resources for purposes beyond those that are currently forecast. Any such unexpected uses of cash resources necessarily shorten the Company's cash runway, as projected without taking into account such matters. In addition, changes in market conditions, including market volatility arising out of dynamic and shifting global trade policies, may reduce the Company's opportunities to raise additional capital, including through the public or private capital markets.

The Company will need to raise additional capital to support its business plans to continue as a going concern within one year after the date that the accompanying condensed consolidated financial statements are issued. If the Company is unable to raise additional capital in a sufficient amount or on acceptable terms in the near term, the Company may have to implement additional, more stringent cost reduction measures to manage liquidity, and the Company may have to significantly delay, scale back, or cease operations, in part or in full. If the Company raises additional funds through the issuance of additional debt or equity securities, including as part of a strategic alternative, it could result in substantial dilution to its existing stockholders and increased fixed payment obligations, and these securities may have rights senior to those of the Company's shares of common stock. These factors raise substantial doubt about the Company's ability to continue as a going concern within one year from the issuance of the condensed consolidated financial statements included in this Quarterly Report. Any of these events could impact the Company's business, financial condition, and prospects.

The Company's financing needs are subject to change depending on, among other things, the success of its trait and product development efforts, the effective execution of its business model, its revenue, and its efforts to effectively manage expenses. The effects of macroeconomic events and potential geopolitical developments on the financial markets and broader economic uncertainties may make obtaining capital through equity or debt financings more challenging and may exacerbate the risk that such capital, if available, may not be available on terms acceptable to the Company.

------

 **CONTRACTUAL OBLIGATIONS, COMMITMENTS, AND CONTINGENCIES**

From time-to-time, the Company may be involved in legal proceedings arising in the ordinary course of business.

The Company is not a party to any material pending legal proceedings as of March 31, 2026.

**CRITICAL ACCOUNTING ESTIMATES** The preceding discussion and analysis of the Company's financial condition and results of operations are based upon its condensed consolidated financial statements and the related disclosures, which have been prepared in accordance with United States GAAP. The preparation of these condensed consolidated financial statements requires the Company to make estimates, assumptions, and judgments that affect the reported amounts in its condensed consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The Company believes the policies discussed in Note 1, Nature of Business & Summary of Significant Accounting Policies, are the most critical to an understanding of its financial condition and results of operations because they require it to make estimates, assumptions, and judgments about matters that are inherently uncertain.

As of March 31, 2026, there were no material changes in the Company's critical accounting policies and estimates as disclosed in its Annual Report.

**Item 4. Controls and Procedures.** 

**Management's Evaluation of Disclosure Controls and Procedures**

Based on an evaluation under the supervision and with the participation of the Company's management, its principal executive officer and principal financial officer have concluded that the Company's disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, were effective as of March 31, 2026.

**Changes in Internal Control over Financial Reporting** No changes in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended March 31, 2026, that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

------

**PART II. OTHER INFORMATION** 

**Item 1. Legal Proceedings.** 

The Company is not a party to any material pending legal proceedings as of March 31, 2026. From time-to-time, the Company may be involved in legal proceedings arising in the ordinary course of business.

**Item 1A. Risk Factors** 

There have been no material changes in risk factors from those disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. *Unregistered Sales of Equity Securities***During the period covered by this Quarterly Report on Form 10-Q, the Company did not issue any unregistered equity securities.

***Issuer Purchases of Equity Securities***

The Company did not repurchase any shares of Class A Common Stock or Class B Common Stock during the period covered by this Quarterly Report on Form 10-Q. During the three months ended March 31, 2026, 32,696 shares of Class A Common Stock were withheld for net share settlement resulting from restricted stock unit award vesting.

**Item 5. Other Information.** During the Company's fiscal quarter ended March 31, 2026, none of the Company's directors or officers adopted, modified, or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" (as each term is defined in Regulation 408(a) of Regulation S-K).

------

**Item 6. Exhibits.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Index of Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| 3.1 | <u>[Second Amended and Restated Certificate of Incorporation of Cibus, Inc., dated May 31, 2023 (incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed on June 1, 2023)](https://www.sec.gov/Archives/edgar/data/1705843/000119312523158545/d487053dex32.htm)</u> |
| 3.2 | <u>[Amended and Restated Bylaws of Cibus, Inc., dated May 31, 2023 (incorporated by reference to Exhibit 3.3 to the Company's Current Report on Form 8-K filed on June 1, 2023)](https://www.sec.gov/Archives/edgar/data/1705843/000119312523158545/d487053dex33.htm)</u> |
| 31.1\* | <u>[Certification of the Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) of the Exchange Act](cbus-20260331xexx311.htm)</u>  |
| 31.2\* | <u>[Certification of the Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) of the Exchange Act](cbus-20260331xexx312.htm)</u>  |
| 32.1\* | <u>[Certification of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](cbus-20260331xexx321.htm)</u>  |
| 101.INS\* | Inline XBRL Instance Document |
| 101.SCH\* | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL\* | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF\* | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB\* | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE\* | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104\* | The cover page for the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, has been formatted in Inline XBRL (contained in Exhibit 101) |

---

_______________________________________

\*&nbsp;&nbsp;&nbsp;&nbsp;Filed herewith

------

**SIGNATURES**

Pursuant to the requirements of the Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on May 14, 2026.

---

| | |
|:---|:---|
| CIBUS, INC. | CIBUS, INC. |
| By: | /s/ Peter Beetham |
| Name: | Peter Beetham |
| Title: | Interim Chief Executive Officer<br>(Principal Executive Officer) |
| By: | /s/ Cornelis (Carlo) Broos |
| Name: | Cornelis (Carlo) Broos |
| Title: | Chief Financial Officer<br>(Principal Financial and Accounting Officer) |

---

## Exhibit 31.1

**Exhibit 31.1** 

**CERTIFICATION PURSUANT TO RULES 13a-l4(a) AND l5d-l4(a)**

**UNDER THE SECURITIES EXCHANGE ACT, AS AMENDED** 

I, Peter Beetham, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of Cibus, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| Date: May 14, 2026 |
| /s/ Peter Beetham |
| Peter Beetham |
| Interim Chief Executive Officer |

---

## Exhibit 31.2

**Exhibit 31.2** 

**CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a)**

**UNDER THE SECURITIES EXCHANGE ACT, AS AMENDED** 

I, Cornelis (Carlo) Broos, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of Cibus, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| Date: May 14, 2026 |
| /s/ Cornelis (Carlo) Broos |
| Cornelis (Carlo) Broos |
| Chief Financial Officer |

---

## Exhibit 32.1

**Exhibit 32.1** 

**CERTIFICATION PURSUANT TO** 

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO** 

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002** 

In connection with the Quarterly Report of Cibus, Inc. (the "Company") on Form 10-Q for the period ended March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), each of the undersigned hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| Date: May 14, 2026 |
| /s/ Peter Beetham |
| Peter Beetham |
| Interim Chief Executive Officer |
| /s/ Cornelis (Carlo) Broos |
| Cornelis (Carlo) Broos |
| Chief Financial Officer |

---

<br>